Eptacog alfa (activated) (NovoSeven, Novo Nordisk A/S) is a recombinant activated factor VII (rFVIIa) used for the treatment and prevention of bleeding episodes in patients with congenital hemophilia with inhibitors.1, 2. This evidence concerns the gene F7 and hemophilia.